Longitudinal SPECT studies on at-risk subjects
| Study | N | Decline | Baseline Clinical Characteristics* | FU | Tracer | |||
|---|---|---|---|---|---|---|---|---|
| Age (yr) | M | MMSE | Ed | |||||
| Borroni et al, 200616 | 27/18 | MCI to AD | 69.4 (7.1) | 22.2 | 27.5 (1.9) | NA | 24 | ECD 1110 MBq |
| Ishiwata et al, 200617 | 12/7 | AAMI to D | 74 | 33.3 | NA | NA | 36 | IMP 222 MBq |
| Johnson et al, 199818 | 45/18 | QA to AD | 72.5 | NA | NA | 14.8 | ≥24 | HMPAO 20 mCi |
| Encinas et al, 200319 | 42/21 | MCI to AD | 76.5 (4.2) | 35.7 | NA | NA | 12–36 | ECD 750 MBq |
| O'Mahony et al, 199420 | 15/11 | MCI to AD | 72.6 | 33.3 | 23.3 | NA | 6 | HMPAO 740 MBq |
| Hirao et al, 200521 | 76/52 | aMCI to AD | 69.0 (8.6) | 48.7 | 26.5 (1.6) | 12.2 (2.9) | 36 | ECD 600 MBq |
| Huang et al, 200322 | 82/28 | MCI to D | 60.9 (9.2) | 45.1 | NA | NA | 26.4 | HMPAO 1000 MBq |
| Huang et al, 200223 | 54/17 | MCI to AD | 61.3 (8.2) | 38.9 | 26.7 (2.2) | NA | 28.9 | HMPAO 1000 MBq |
Note:—ECD indicates ethyl cysteinate dimer; IMP, iodoamphetamine; HMPAO, hexamethyl propyleneamine oxime; QA, questionable AD; SPECT, single-photon emission tomography.
* Each cell was listed as mean value (SD).